Imugene (ASX:IMU) received clearance from the Cohort Review Committee to escalate the dose level in the intravenous combination segment of its phase one onCARlytics trial, targeting adult patients with advanced or metastatic solid tumors, according to a Thursday Australian bourse filing.
The trial seeks to evaluate the safety and efficacy of different routes of administration, intratumoral injection, and intravenous infusion of either onCARlytics, a CD19-expressing oncolytic virus, alone, or in combination with CD19-targeting bispecific monoclonal antibody blinatumomab, which is a cancer immunotherapy.
The IV combination arm will progress to a higher dose level after the completion of the safety observation period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。